Positron emission computed tomography targeting urokinase plasminogen activator receptor (uPAR) in cancer: a systematic review

References

• Palfree RG. The urokinase-type plasminogen activator receptor is a member of the ly-6 superfamily. Immunol Today. 1991;12(5):170. doi: 10.1016/S0167-5699(05)80051-9
   PubMedGoogle Scholar
• Behrendt N, Rønne E, Danø K. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol Chem Hoppe-Seyler. 1995;376(5):269–279.
   PubMed Web of Science ®Google Scholar
• Genua M, D’Alessio S, Cibella J, et al. The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation. Gut. 2015;64(4):589–600. doi: 10.1136/gutjnl-2013-305933
   PubMed Web of Science ®Google Scholar
• Multhaupt HA, Mazar A, Cines DB, et al. Expression of urokinase receptors by human trophoblast. A histochemical and ultrastructural analysis. Lab Invest. 1994;71(3):392–400.
   PubMed Web of Science ®Google Scholar
• Zhai B-T, Tian H, Sun J, et al. Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer. J Transl Med. 2022; 20(1):135. doi: 10.1186/s12967-022-03329-3
   PubMed Web of Science ®Google Scholar
• Rowe SP, Pomper MG. Molecular imaging in oncology: Current impact and future directions. CA Cancer J Clin. 2022;72(4):333–352. doi: 10.3322/caac.21713
   PubMed Web of Science ®Google Scholar
• Filippi L, Di Costanzo GG, Tortora R, et al. Prognostic value of neutrophil-to-lymphocyte ratio and its correlation with fluorine-18-fluorodeoxyglucose metabolic parameters in intrahepatic cholangiocarcinoma submitted to 90Y-radioembolization. Nucl Med Commun. 2020;41(1):78–86. doi: 10.1097/MNM.0000000000001123
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;n71. doi: 10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar
• Persson M, Skovgaard D, Brandt-Larsen M, et al. First-in-human uPAR PET: imaging of cancer aggressiveness. Theranostics. 2015; 5(12):1303–1316. doi: 10.7150/thno.12956
   PubMed Web of Science ®Google Scholar
• Skovgaard D, Persson M, Brandt-Larsen M, et al. Safety, dosimetry, and tumor detection ability of 68Ga-NOTA-AE105: first-in-human study of a novel radioligand for uPAR PET imaging. J Nucl Med. 2017;58(3):379–386. doi: 10.2967/jnumed.116.178970
   PubMed Web of Science ®Google Scholar
• Risør LM, Clausen MM, Ujmajuridze Z, et al. Prognostic value of urokinase-type plasminogen activator receptor PET/CT in head and neck squamous cell carcinomas and comparison with 18F-FDG PET/CT: a single-center prospective study. J Nucl Med. 2022;63(8):1169–1176. doi: 10.2967/jnumed.121.262866
   PubMed Web of Science ®Google Scholar
• Fosbøl MØ, Kurbegovic S, Johannesen HH, et al. Urokinase-type plasminogen activator receptor (uPAR) PET/MRI of prostate cancer for noninvasive evaluation of aggressiveness: comparison with Gleason score in a prospective phase 2 clinical trial. J Nucl Med. 2021;62(3):354–359. doi: 10.2967/jnumed.120.248120
   PubMed Web of Science ®Google Scholar
• Fosbøl MØ, Mortensen J, Petersen PM, et al. uPAR PET/CT for prognostication and response assessment in patients with metastatic castration-resistant prostate cancer undergoing radium-223 therapy: a prospective phase II study. Diagn (Basel). 2021;11(6):1087. doi: 10.3390/diagnostics11061087
   PubMedGoogle Scholar
• Risør LM, Binderup T, Fosbøl MØ, et al. Urokinase-type plasminogen activator receptor (uPAR) assessed by liquid biopsies and PET/CT for prognostication in head and neck cancer patients. Sci Rep. 2022;12(1):19126. doi: 10.1038/s41598-022-21175-7
   PubMed Web of Science ®Google Scholar
• Carlsen EA, Loft M, Loft A, et al. Prospective phase II trial of prognostication by 68Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: implications for uPAR-targeted therapy. J Nucl Med. 2022;63(9):1371–1377. doi: 10.2967/jnumed.121.263177
   PubMed Web of Science ®Google Scholar
• Nantajit D, Chailapakul P, Bawornpatarapakorn S, et al. Prognostic significance of uPA and uPAR expression in patients with cervical cancer undergoing radiotherapy. Oncol Lett. 2021;21(5):423. doi: 10.3892/ol.2021.12684
   PubMed Web of Science ®Google Scholar
• Li Santi A, Napolitano F, Montuori N, et al. The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications. Int J Mol Sci. 2021; 22(8):4111. doi: 10.3390/ijms22084111
   PubMed Web of Science ®Google Scholar
• Liu G, Mao W, Yu H, et al. One-stop [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 total-body PET/CT examination with dual-low activity: a feasibility study. Eur J Nucl Med Mol Imaging. 2023;50(8):2271–2281. doi: 10.1007/s00259-023-06207-2
   PubMed Web of Science ®Google Scholar
• Filippi L, Dimitrakopoulou-Strauss A, Evangelista L, et al. Long axial field-of-view PET/CT devices: are we ready for the technological revolution? Expert Rev Med Devices. 2022;19(10):739–743. doi: 10.1080/17434440.2022.2141111
   PubMed Web of Science ®Google Scholar
• Alongi P, Laudicella R, Lanzafame H, et al. PSMA and Choline PET for the assessment of response to therapy and survival outcomes in prostate cancer patients: a systematic review from the literature. Cancers (Basel). 2022;14(7):1770. doi: 10.3390/cancers14071770
   PubMed Web of Science ®Google Scholar
• Filippi L, Spinelli GP, Chiaravalloti A, et al. Prognostic value of 18F-Choline PET/CT in patients with metastatic castration-resistant prostate cancer treated with radium-223. Biomedicines. 2020;8(12):555. doi: 10.3390/biomedicines8120555
   PubMed Web of Science ®Google Scholar
• Brawley S, Mohan R, Nein CD. Localized prostate cancer: treatment options. Am Fam Physician. 2018;97(12):798–805.
   PubMed Web of Science ®Google Scholar
• Kearns JT, Helfand BT. Is active surveillance too active? Curr Urol Rep. 2023;24(10):463–469. doi: 10.1007/s11934-023-01177-2
   PubMed Web of Science ®Google Scholar
• Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208–1216. doi: 10.1016/S0140-6736(20)30314-7
   PubMed Web of Science ®Google Scholar
• Evangelista L, Zattoni F, Rossi E, et al. Early detection of prostate cancer relapse by biochemistry and diagnostic imaging. Q J Nucl Med Mol Imaging. 2015;59(4):359–373.
   PubMed Web of Science ®Google Scholar
• Mokoala K, Lawal I, Lengana T, et al. PSMA theranostics: science and practice. Cancers (Basel). 2021;13(15):3904. doi: 10.3390/cancers13153904
   PubMed Web of Science ®Google Scholar
• Filippi L, Chiaravalloti A, Schillaci O, et al. The potential of PSMA-targeted alpha therapy in the management of prostate cancer. Expert Rev Anticancer Ther. 2020;20(10):823–829. doi: 10.1080/14737140.2020.1814151
   PubMed Web of Science ®Google Scholar
• Uprimny C, Kroiss AS, Decristoforo C, et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging. 2017;44(6):941–949.
   PubMed Web of Science ®Google Scholar
• Sathekge M, Lengana T, Maes A, et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate carcinoma: preliminary results on differences between black and white South-Africans. Eur J Nucl Med Mol Imaging. 2018;45(2):226–234.
   PubMed Web of Science ®Google Scholar
• Alevroudis E, Spei M-E, Chatziioannou SN, et al. Clinical utility of 18F-FDG PET in neuroendocrine tumors prior to peptide receptor radionuclide therapy: a systematic review and meta-analysis. Cancers (Basel). 2021;13(8):1813. doi: 10.3390/cancers13081813
   PubMed Web of Science ®Google Scholar
• Urso L, Panareo S, Castello A, et al. Glucose metabolism modification induced by radioligand therapy with [177Lu]Lu/[90Y]Y-DOTATOC in advanced neuroendocrine neoplasms: a prospective pilot study within FENET-2016 trial. Pharmaceutics. 2022;14(10):2009. doi: 10.3390/pharmaceutics14102009
   PubMed Web of Science ®Google Scholar
• Persson M, Rasmussen P, Madsen J, et al. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts. Nucl Med Biol. 2012;39(7):962–969. doi: 10.1016/j.nucmedbio.2012.05.007
   PubMed Web of Science ®Google Scholar
• Persson M, Juhl K, Rasmussen P, et al. uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer. Mol Pharm. 2014;11(8):2796–2806.
   PubMedGoogle Scholar
• Berg D, Wolff C, Malinowsky K, et al. Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR. J Cell Physiol. 2012;227(1):204–212. doi: 10.1002/jcp.22718
   PubMed Web of Science ®Google Scholar
• Al-Hassan NN, Behzadian A, Caldwell R, et al. Differential roles of uPAR in peritoneal ovarian carcinomatosis. Neoplasia. 2012;14(4):259–270.
   PubMed Web of Science ®Google Scholar
• Tecimer C, Doering DL, Goldsmith LJ, et al. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer. Gynecol Oncol. 2001;80(1):48–55. doi: 10.1006/gyno.2000.6015
   PubMed Web of Science ®Google Scholar